MX2016014384A - Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado. - Google Patents

Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.

Info

Publication number
MX2016014384A
MX2016014384A MX2016014384A MX2016014384A MX2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A MX 2016014384 A MX2016014384 A MX 2016014384A
Authority
MX
Mexico
Prior art keywords
apremilast
liver
treatment
function abnormality
liver disease
Prior art date
Application number
MX2016014384A
Other languages
English (en)
Inventor
Stevens Randall
HOUGH Douglas
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2016014384A publication Critical patent/MX2016014384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Se describen métodos para tratar, manejar o prevenir la enfermedad del hígado. Los métodos específicos abarcan la administración de Apremilast, solo o en combinación con agentes activos adicionales o regímenes de tratamiento.
MX2016014384A 2014-06-23 2015-06-22 Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado. MX2016014384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016013P 2014-06-23 2014-06-23
PCT/US2015/036898 WO2015200177A1 (en) 2014-06-23 2015-06-22 Apremilast for the treatment of a liver disease or a liver function abnormality

Publications (1)

Publication Number Publication Date
MX2016014384A true MX2016014384A (es) 2017-01-20

Family

ID=53674276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014384A MX2016014384A (es) 2014-06-23 2015-06-22 Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.

Country Status (6)

Country Link
US (1) US10300042B2 (es)
EP (1) EP3157520B1 (es)
JP (1) JP6687550B2 (es)
ES (1) ES2749433T3 (es)
MX (1) MX2016014384A (es)
WO (1) WO2015200177A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7048863B2 (ja) * 2016-08-26 2022-04-06 武田薬品工業株式会社 非アルコール性脂肪肝疾患の治療法
WO2018069422A1 (en) * 2016-10-12 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non-alcoholic fatty liver disease
CA3138473A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
WO2022182895A1 (en) * 2021-02-26 2022-09-01 Rutgers, The State University Of New Jersey Compounds and methods for treating congenital erythropoietic porphyria
WO2022251620A1 (en) * 2021-05-28 2022-12-01 Amgen Inc. Formulations of apremilast

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3322755A (en) 1964-03-10 1967-05-30 Boehringer Sohn Ingelheim Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
DE2051871A1 (en) 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS536156B2 (es) 1972-10-30 1978-03-04
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4162316A (en) 1975-03-12 1979-07-24 Dainippon Pharmaceutical Co., Ltd. 1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
US4001237A (en) 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4001238A (en) 1976-02-18 1977-01-04 Bristol-Myers Company 1,3,4-oxadiazole amides
US4047404A (en) 1976-11-17 1977-09-13 Tanno Senshoku Kogyo Co., Ltd. Printed fabric washing apparatus
US4101548A (en) 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4209623A (en) 1978-06-07 1980-06-24 Bristol-Myers Company Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
GB2063249A (en) 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3770095D1 (de) 1986-08-21 1991-06-20 Pfizer Chinazolindione und pyridopyrimidindione.
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB8909560D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Chemical compounds
GB8923131D0 (en) 1989-10-13 1989-11-29 Smith Kline French Lab Chemical compounds
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5401774A (en) 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5354571A (en) 1992-04-27 1994-10-11 Rheon Automatic Machinery Co., Ltd. Method for aligning and bending individual round elongated dough pieces
US5243826A (en) 1992-07-01 1993-09-14 Apd Cryogenics Inc. Method and apparatus for collecting liquid cryogen
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO1995007267A1 (fr) 1993-09-10 1995-03-16 Eisai Co., Ltd. Compose de quinazoline
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5608914A (en) 1994-11-21 1997-03-11 Keesler; Daren Headcover
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
DE19501481A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
DE19501480A1 (de) 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
DE19501482A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
US5614530A (en) 1995-03-10 1997-03-25 Sterling Winthrop Inc. Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
ES2175079T3 (es) 1995-04-10 2002-11-16 Fujisawa Pharmaceutical Co Derivados de indol utiles como inhibidores de cgmp-pde.
TW381092B (en) 1995-07-07 2000-02-01 Otsuka Pharma Co Ltd Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
JP3063162B2 (ja) 1995-12-28 2000-07-12 藤沢薬品工業株式会社 ベンズイミダゾール誘導体
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
AU724809B2 (en) 1996-08-30 2000-09-28 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
WO1998014448A1 (fr) 1996-10-04 1998-04-09 Kyorin Pharmaceutical Co., Ltd. Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
KR100239800B1 (ko) 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
PT975347E (pt) 1997-02-28 2008-05-23 Nycomed Gmbh Combinação sinérgica de inibidores da pde e agonistas da adenilato ciclase ou agonistas da guanil ciclise
BR9815895A (pt) 1997-07-31 2001-01-16 Celgene Corp Substituido ácido alcanohidroxamico e método para reduzir nìveis de tnf alfa
US6034089A (en) 1997-10-03 2000-03-07 Merck & Co., Inc. Aryl thiophene derivatives as PDE IV inhibitors
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
AU751453C (en) 1997-11-25 2003-04-10 Warner-Lambert Company Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
JP2002537383A (ja) 1999-02-25 2002-11-05 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害化合物、組成物および治療方法
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
AU770918B2 (en) 1999-12-23 2004-03-11 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2718601A1 (en) * 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2334639B1 (en) 2008-09-10 2013-01-23 Celgene Corporation Processes for the preparation of aminosulfone compounds
PL2443089T3 (pl) 2009-06-18 2014-09-30 Concert Pharmaceuticals Inc Deuterowane pochodne izoindolino-1,3-dionu jako inhibitory pde4 i tnf-alfa
CA2777719A1 (en) * 2009-11-19 2011-05-26 Celgene Corporation Apremilast for the treatment of sarcoidosis
CN104761484B (zh) 2014-11-24 2018-03-27 上海优拓医药科技有限公司 一种稳定的不含溶剂化物的阿普司特晶型ii及其制备方法

Also Published As

Publication number Publication date
EP3157520A1 (en) 2017-04-26
US20170143671A1 (en) 2017-05-25
US10300042B2 (en) 2019-05-28
JP2017526628A (ja) 2017-09-14
ES2749433T3 (es) 2020-03-20
WO2015200177A1 (en) 2015-12-30
JP6687550B2 (ja) 2020-04-22
EP3157520B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
MX2015008685A (es) Tratamiento de artritis psoriasica usando apremilast.
PL3554631T3 (pl) Leczenie pacjentów polami ttfields ze zoptymalizowanymi pozycjami elektrod z wykorzystaniem odkształcalnych matryc
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
IL249370A0 (en) Fap-enabled medical substances and related uses
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2020014121A (es) Agonistas parciales del receptor de insulina.
NZ730809A (en) Methods for treating filoviridae virus infections
MY187540A (en) Compounds active towards bromodomains
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
MX2015011428A (es) Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX2016014384A (es) Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
MX2017002489A (es) Agentes terapeuticos humanos.
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
PH12020550185A1 (en) Semaglutide in medical therapy
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
EP3538888A4 (en) COMBINATION THERAPIES FOR TREATING BIPOLAR DISORDER AND METHOD FOR USE THEREOF
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
TH1501007436A (th) สารรวมของสารอนุพันธ์อิมิดาโซไพริดาซีนและสารแบ่งตัวสำหรับการรักษาของมะเร็ง
UA104614U (uk) Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: AMGEN (EUROPE) GMBH